ABSTRACT
Fanconi anemia (FA) is an inherited disease associated with marked hematopoietic stem and progenitor cell (HSPC) defects. Ongoing clinical trials have shown that lentiviral-mediated gene therapy can ameliorate bone marrow failure (BMF) in non-conditioned FA patients thanks to the proliferative advantage of corrected FA HSPCs. Here we investigated whether gene therapy can revert affected molecular pathways in diseased HSPCs, a question not previously addressed in any HSC gene therapy trial. Single-cell RNA sequencing was performed in chimeric populations of corrected and uncorrected HSPCs coexisting in BM of gene therapy treated FA patients. Our study demonstrates that gene therapy reverts the transcriptional signature of FA HSPCs, which then resembles the transcriptional program of healthy donor HSPCs. This includes a downregulated expression of TGF-β and p21, typically upregulated in FA HSPCs, and upregulation of DNA damage response and telomerase maintenance pathways. Our results show for the first time the potential of gene therapy to rescue defects in the HSPC transcriptional program from patients with inherited diseases, in this case in FA characterized by BMF and cancer predisposition.
Competing Interest Statement
The Hematopoietic Innovative Therapies Division at CIEMAT receives funding and has licensed the PGK-FANCA-WPRE* lentiviral vector to Rocket Pharmaceuticals. J.A.B. and J.Se. are consultants for Rocket Pharmaceuticals. E.N. and J.D.S. are employees of Rocket Pharmaceuticals. P.R., S.N., J.S and J.A.B. are inventors on patents filed by CIEMAT, CIBERER and Fundacion Jimenez Diaz, and may be entitled to receive financial benefits from the licensing of such patents. The rest of the authors declare that they have no competing interests.
Funding Statement
This work was supported by grants from the European Commissions Seventh Framework Program (HEALTH-F5-2012-305421) to the EUROFANCOLEN Consortium J.B. and J.Se; from Ministerio de Economia, Comercio y Competitividad and Fondo Europeo de Desarrollo Regional (RTI2018-097125-B-I00 to P.R. and S.N.); from Gobierno de Navarra, Departamento de Desarrollo Economico y Empresarial (AGATA 0011-1411-2020-000010); from Instituto de Salud Carlos III (ISCIII) and co-financed by FEDER CIBERONC (CB16/12/00489 and CB16/12/00225); Redes de Investigacion Cooperativa (TERCEL RD16/0011/0005) and from Consejeria de Educacion, Juventud y Deporte de la Comunidad de Madrid (AvanCell Project; B2017/BMD3692). M.A. was supported by a PhD Fellowship from Ministerio de Ciencia, Innovacion y Universidades (FPU18/05488). CIBERER and CIBERONC are initiatives of the Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the clinical research ethics committee of Clinica Universidad de Navarra.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The updated version includes: - Single-cell RNA-seq profiling of one additional Fanconi Anemia patient. The analysis was updated accordingly. - Several experiments to validate hypothesis generated from the bioinformatic analysis. (e.g. telomere length)
Data Availability
The authors declare that the data supporting the findings of this study will be made available before the manuscript publication. Also data will be made available upon request, and following GDPR guidelines, after peer-review publication.
